Kevin R Bewley
Overview
Explore the profile of Kevin R Bewley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suligoj T, Coombes N, Booth C, Savva G, Bewley K, Funnell S, et al.
Access Microbiol
. 2024 Dec;
6(9).
PMID: 39697363
The coronavirus 2019 pandemic has highlighted the importance of physiologically relevant models to assist preclinical research. Here, we describe the adaptation of a human alveolus microphysiological system (MPS) model consisting...
2.
Bown A, Sweed A, Catton M, Nelthorpe-Cowne J, Conti-Frith H, Elderfield R, et al.
Int J Infect Dis
. 2023 Dec;
139:168-170.
PMID: 38151115
We evaluated the performance of 12 lateral flow devices by assessing their analytical sensitivity for SARS-CoV-2 variant BA.2.86. Kits from ACON, Orient Gene, Xiamen Biotime, Getein, and SureScreen detected variant...
3.
Davies E, Ryan K, Bewley K, Coombes N, Salguero F, Carnell O, et al.
Viruses
. 2023 May;
15(5).
PMID: 37243219
The ongoing emergence of SARS-CoV-2 virus variants remains a source of concern because it is accompanied by the potential for increased virulence as well as evasion of immunity. Here we...
4.
Ryan K, Bewley K, Watson R, Burton C, Carnell O, Cavell B, et al.
PLoS Pathog
. 2023 Apr;
19(4):e1011293.
PMID: 37014911
The mutation profile of the SARS-CoV-2 Omicron (lineage BA.1) variant posed a concern for naturally acquired and vaccine-induced immunity. We investigated the ability of prior infection with an early SARS-CoV-2...
5.
Handley A, Ryan K, Davies E, Bewley K, Carnell O, Challis A, et al.
Viruses
. 2023 Mar;
15(3).
PMID: 36992457
The golden Syrian hamster () is now commonly used in preclinical research for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the assessment of vaccines, drugs...
6.
Coombes N, Bewley K, Le Duff Y, Hurley M, Smith L, Weldon T, et al.
Viruses
. 2023 Mar;
15(3).
PMID: 36992342
In the summer of 2020, it became clear that the genetic composition of SARS-CoV-2 was changing rapidly. This was highlighted by the rapid emergence of the D614G mutation at that...
7.
Hartley M, Norville I, Richards M, Barnes K, Bewley K, Vipond J, et al.
Front Microbiol
. 2021 Dec;
12:760698.
PMID: 34917048
Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci....
8.
Parry H, Tut G, Bruton R, Faustini S, Stephens C, Saunders P, et al.
Elife
. 2021 Sep;
10.
PMID: 34586068
Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age...
9.
Bewley K, Gooch K, Thomas K, Longet S, Wiblin N, Hunter L, et al.
Sci Adv
. 2021 Sep;
7(37):eabg7996.
PMID: 34516768
There is an urgent requirement for safe and effective vaccines to prevent COVID-19. A concern for the development of new viral vaccines is the potential to induce vaccine-enhanced disease (VED)....
10.
Lambe T, Spencer A, Thomas K, Gooch K, Thomas S, White A, et al.
Commun Biol
. 2021 Jul;
4(1):915.
PMID: 34312487
Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against...